Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Repisalud
Publication Artículo científico (JournalArticle)

Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers.

  • Mavaddat, Nasim
  • Antoniou, Antonis C
  • Mooij, Thea M
  • Hooning, Maartje J
  • Heemskerk-Gerritsen, Bernadette A
  • Noguès, Catherine
  • Gauthier-Villars, Marion
  • Caron, Olivier
  • Gesta, Paul
  • Pujol, Pascal
  • Lortholary, Alain
  • Barrowdale, Daniel
  • Frost, Debra
  • Evans, D Gareth
  • Izatt, Louise
  • Adlard, Julian
  • Eeles, Ros
  • Brewer, Carole
  • Tischkowitz, Marc
  • Henderson, Alex
  • Cook, Jackie
  • Eccles, Diana
  • van Engelen, Klaartje
  • Mourits, Marian J E
  • Ausems, Margreet G E M
  • Koppert, Linetta B
  • Hopper, John L
  • John, Esther M
  • Chung, Wendy K
  • Andrulis, Irene L
  • Daly, Mary B
  • Buys, Saundra S
  • Caldes, Trinidad
  • Jakubowska, Anna
  • Simard, Jacques
  • Singer, Christian F
  • Tan, Yen
  • Olah, Edith
  • Navratilova, Marie
  • Foretova, Lenka
  • Gerdes, Anne-Marie
  • Roos-Blom, Marie-José
  • Van Leeuwen, Flora E
  • Arver, Brita
  • Olsson, Håkan
  • Schmutzler, Rita K
  • Engel, Christoph
  • Kast, Karin
  • Phillips, Kelly-Anne
  • Terry, Mary Beth
  • Milne, Roger L
  • Goldgar, David E
  • Rookus, Matti A
  • Andrieu, Nadine
  • Easton, Douglas F
  • Benitez, Javier
The effect of risk-reducing salpingo-oophorectomy (RRSO) on breast cancer risk for BRCA1 and BRCA2 mutation carriers is uncertain. Retrospective analyses have suggested a protective effect but may be substantially biased. Prospective studies have had limited power, particularly for BRCA2 mutation carriers. Further, previous studies have not considered the effect of RRSO in the context of natural menopause. A multi-centre prospective cohort of 2272 BRCA1 and 1605 BRCA2 mutation carriers was followed for a mean of 5.4 and 4.9 years, respectively; 426 women developed incident breast cancer. RRSO was modelled as a time-dependent covariate in Cox regression, and its effect assessed in premenopausal and postmenopausal women. There was no association between RRSO and breast cancer for BRCA1 (HR = 1.23; 95% CI 0.94-1.61) or BRCA2 (HR = 0.88; 95% CI 0.62-1.24) mutation carriers. For BRCA2 mutation carriers, HRs were 0.68 (95% CI 0.40-1.15) and 1.07 (95% CI 0.69-1.64) for RRSO carried out before or after age 45 years, respectively. The HR for BRCA2 mutation carriers decreased with increasing time since RRSO (HR = 0.51; 95% CI 0.26-0.99 for 5 years or longer after RRSO). Estimates for premenopausal women were similar. We found no evidence that RRSO reduces breast cancer risk for BRCA1 mutation carriers. A potentially beneficial effect for BRCA2 mutation carriers was observed, particularly after 5 years following RRSO. These results may inform counselling and management of carriers with respect to RRSO.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Characterization of mesenchymal stem cells in sheep naturally infected with scrapie

  • Mediano, Diego R.
  • Sanz-Rubio, David
  • Bolea, Rosa
  • Marín, Belén
  • Vázquez, Francisco J.
  • Remacha, Ana R.
  • López-Pérez, Óscar
  • Fernández-Borges, Natalia
  • Castilla, Joaquín
  • Zaragoza, Pilar
  • Badiola, Juan J.
  • Rodellar, Clementina
  • Martín-Burriel, Inmaculada
Mesenchymal stem cells (MSCs) can be infected with prions and have been proposed as in vitro cell-based models for prion replication. In addition, autologous MSCs are of interest for cell therapy in neurodegenerative diseases. To the best of our knowledge, the effect of prion diseases on the characteristics of these cells has never been investigated. Here, we analysed the properties of MSCs obtained from bone marrow (BM-MSCs) and peripheral blood (PB-MSCs) of sheep naturally infected with scrapie — a large mammal model for the study of prion diseases. After three passages of expansion, MSCs derived from scrapie animals displayed similar adipogenic, chondrogenic and osteogenic differentiation ability as cells from healthy controls, although a subtle decrease in the proliferation potential was observed. Exceptionally, mesenchymal markers such as CD29 were significantly upregulated at the transcript level compared with controls. Scrapie MSCs were able to transdifferentiate into neuron-like cells, but displayed lower levels of neurogenic markers at basal conditions, which could limit this potential. The expression levels of cellular prion protein (PrPC) were highly variable between cultures, and no significant differences were observed between control and scrapie-derived MSCs. However, during neurogenic differentiation the expression of PrPC was upregulated in MSCs. This characteristic could be useful for developing in vitro models for prion replication. Despite the infectivity reported for MSCs obtained from scrapie-infected mice and Creutzfeldt–Jakob disease patients, protein misfolding cyclic amplification did not detect PrPSc in BM- or PB-MSCs from scrapie-infected sheep, which limits their use for in vivo diagnosis for scrapie.